Unexplained chronic increase in transaminase levels;Augmentation chronique inexpliquée des transaminases

Hepato-Gastro

Volumn 10, Issue 4, 2003, Pages 257-263

  Valla, Dominique Charles ^a  

^a INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL CONSUMPTION; AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AUTOIMMUNE DISEASE; CHRONIC DISEASE; CHRONIC LIVER DISEASE; CLINICAL EXAMINATION; CLINICAL FEATURE; ENZYME ACTIVITY; HEPATITIS B; HEPATITIS C; HUMAN; INSULIN RESISTANCE; SHORT SURVEY;

EID: 0041474756     PISSN: 12537020     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (38)

1. Friedman LS, Dienstag JL, Watkins E, Hinkle CA, Spiers JA, Rieder SV, et al. Evaluation of blood donors with elevated serum alanine aminotransferase levels. Ann Intern Med 1987; 107: 137-44.
2. Piton A, Poynard T, Imbert-Bismut F, Khalil L, Delattre J, Pelissier E, et al. Factors associated with serum alanine transaminase activity in healthy subjects: consequences for the definition of normal values, for selection of blood donors, and for patients with chronic hepatitis C. Multivirc Group. Hepatology 1998; 27: 1213-9.
3. Prati D, Taioli E, Zanella A, Della Torre E, Butelli S, Del Vecchio E, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 2002; 137: 1-10.
4. Goenner S, Corriat-Boutron A, Pelletier G, Legrand A, Buffet C. Macroaspartate aminotransferase: study of 5 cases and review of the literature. Gastroenterol Clin Biol 1998; 22: 549-53.
5. Couzigou P, Latapie JL, Fleury B, Climas MT, Le Moigne F, Crockett E, et al. Evolution of serum gammaglutamyl transpeptidase activity in treated hyperthyroid and hypothyroid patients. Gastroenterol Clin Biol 1984; 8: 458-63.
6. Lesur G, Barete S, Le Parc JM, Dupay P, Paolaggi JB. Addison disease: a rare cause of elevated serum aminotransferase activity. Gastroenterol Clin Biol 1996; 20: 515-6.
7. Volta U, De Franceschi L, Lari F, Molinaro N, Zoli M, Bianchi FB. Coeliac disease hidden by cryptogenic hypertransaminasaemia. Lancet 1998; 352: 26-9.
8. Bardella MT, Fraquelli M, Quatrini M, Molteni N, Bianchi P, Conte D. Prevalence of hypertransaminasemia in adult celiac patients and effect of gluten-free diet. Hepatology 1995; 22: 833-6.
9. Bardella MT, Vecchi M, Conte D, Del Ninno E, Fraquelli M, Pacchetti S, et al. Chronic unexplained hypertransaminasemia may be caused by occult celiac disease. Hepatology 1999; 29: 654-7.
10. Czaja AJ, Carpenter HA, Santrach PJ, Moore SB, Homburger HA. The nature and prognosis of severe cryptogenic chronic active hepatitis. Gastroenterology 1993; 104: 1755-61.
11. Kaymakoglu S, Cakaloglu Y, Demir K, Turkoglu S, Badur S, Gurel S, et al. Is severe cryptogenic chronic hepatitis similar to autoimmune hepatitis? J Hepatol 1998; 28: 78-83.
12. Manns MP, Strassburg CP. Autoimmune hepatitis: clinical challenges. Gastroenterology 2001; 120: 1502-17.
13. Czaja AJ, Freese DK. Diagnosis and treatment of autoimmune hepatitis. Hepatology 2002; 36: 479-97.
14. Lee YM, Kaplan MM. Management of primary sclerosing cholangitis. Am J Gastroenterol 2002; 97: 528-34.
15. Wee A, Ludwig J. Pericholangitis in chronic ulcerative colitis: primary sclerosing cholangitis of the small bile ducts? Ann Intern Med 1985; 102: 581-7.
16. Munoz SJ. Use of hepatitis B core antibody-positive donors for liver transplantation. Liver Transpl 2002; 8: S82-7.
17. Hu KQ. Occult hepatitis B virus infection and its clinical implications. J Virol Hepat 2002; 9: 243-57.
18. Brechot C, Thiers V, Kremsdorf D, Nalpas B, Pol S, Paterlini-Brechot P. Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: clinically significant or purely "occult"? Hepatology 2001; 34: 194-203.
19. Chemin I, Zoulim F, Merle P, Arkhis A, Chevallier M, Kay A, et al. High incidence of hepatitis B infections among chronic hepatitis cases of unknown aetiology. J Hepatol 2001; 34: 447-54.
20. Marcellin P, Martinot-Peignoux M, Gabriel F, Branger M, Degott C, Elias A, et al. Chronic non-B, non-C hepatitis among blood donors assessed with HCV third generation tests and polymerase chain reaction. J Hepatol 1993; 19: 167-70.
21. Schmidt WN, Wu P, Cederno J, Mitros FA, LaBrecque DR, Stapleton JT. Surreptitious hepatitis C virus (HCV) infection detected in the majority of patients with cryptogenic chronic hepatitis and negative HCV antibody tests. J Infect Dis 1997; 176: 27-33.
22. Romeo R, Pol S, Demeret C, Thiers V, Kremsdorf D, Cuillerier E, et al. Evidence of non-A, non-B, non-C infection in chronic hepatitis by polymerase chain reaction testing for hepatitis B and C viruses. J Hepatol 1995; 22: 125-9.
23. Hammel P, Marcellin P, Martinot-Peignoux M, Pham BN, Degott C, Level R, et al. Etiology of chronic hepatitis in France: predominant role of hepatitis C virus. J Hepatol 1994; 21: 618-23.
24. Cacciola I, Pollicino T, Squadrito G, Cerenzia G, Orlando ME, Raimondo G. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N Engl J Med 1999; 341: 22-6.
25. Dossing M. Occupational toxic liver damage. J Hepatol 1986; 3: 131-5.
26. Redlich CA, West AB, Fleming L, True LD, Cullen MR, Riely CA. Clinical and pathological characteristics of hepatotoxicity associated with occupational exposure to dimethylformamide. Gastroenterology 1990; 99: 748-57.
27. Cotrim HP, Andrade ZA, Parana R, Portugal M, Lyra LG, Freitas LA. Nonalcoholic steatohepatitis: a toxic liver disease in industrial workers. Liver 1999; 19: 299-304.
28. Marchesini G, Brizi M, Morselli-Labate AM, Bianchi G, Bugianesi E, McCullough AJ, et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 1999; 107: 450-5.
29. Chitturi S, Abeygunasekera S, Farrell GC, Holmes-Walker J, Hui JM, Fung C, et al, NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002; 35: 373-9.
30. Wallace TM, Matthews DR. The assessment of insulin resistance in man. Diabet Med 2002; 19: 527-34.
31. Corrao G, Arico S, Zambon A, Torchio P, Lepore AR, Busellu G, et al. Is alcohol a risk factor for liver cirrhosis in HBsAg and anti-HCV negative subjects? Collaborative Groups for the Study of Liver Diseases in Italy. J Hepatol 1997; 27: 470-6.
32. Naveau S, Giraud V, Borotto E, Aubert A, Capron F, Chaput JC. Excess weight risk factor for alcoholic liver disease. Hepatology 1997; 25: 108-11.
33. Fletcher LM, Kwoh-Gain I, Powell EE, Powell LW, Halliday JW. Markers of chronic alcohol ingestion in patients with nonalcoholic steatohepatitis: an aid to diagnosis. Hepatology 1991; 13: 455-9.
34. Steindl P, Ferenci P, Dienes HP, Grimm G, Pabinger I, Madl C, et al. Wilson's disease in patients presenting with liver disease: a diagnostic challenge. Gastroenterology 1997; 113: 212-8.
35. Gow PJ, Smallwood RA, Angus PW, Smith AL, Wall AJ, Sewell RB. Diagnosis of Wilson's disease: an experience over three decades. Gut 2000; 46: 415-9.
36. Graziadei IW, Joseph JJ, Wiesner RH, Therneau TM, Batts KP, Porayko MK. Increased risk of chronic liver failure in adults with heterozygous alpha 1-antitrypsin deficiency. Hepatology 1998; 28: 1058-63.
37. Fischer HP, Ortiz-Pallardo ME, Ko Y, Esch C, Zhou H. Chronic liver disease in heterozygous alpha1-antitrypsin deficiency PiZ. J Hepatol 2000; 33: 883-92.
38. Hillaire S, Bonte E, Denninger MH, Casadevall N, Cadranel JF, Lebrec D, et al. Idiopathic non-cirrhotic intrahepatic portal hypertension in the West: a re-evaluation in 28 patients. Gut 2002; 51: 275-80.